Roche unit Genentech's Perjeta shows extended survival in breast cancer patients

theflyonthewall.com

Genentech, a member of the Roche Group (RHHBY), announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta, Herceptin and docetaxel chemotherapy significantly extended the overall survival of people with previously untreated HER2-positive metastatic breast cancer, compared to Herceptin, chemotherapy and placebo. Results showed that the risk of death was reduced by 34% for people who received Perjeta, Herceptin and chemotherapy, compared to those who received Herceptin and chemotherapy. At the time of the analysis, median overall survival had not yet been reached in people receiving the Perjeta combination, as more than half of these people continued to survive. Median overall survival was 37.6 months for people who received Herceptin and chemotherapy. Based on these data, people receiving Herceptin and chemotherapy in CLEOPATRA have been offered the option to receive Perjeta. No new safety signals were observed in the study. :theflyonthewall.com

View Comments (0)